Abstract. The SARS-CoV-2 virus has emerged and rapidly evolved into a current global pandemic. Although bacterial and fungal coinfections have been associated with COVID-19, little is known about parasitic infection. We report a case of a COVID-19 patient who developed disseminated strongyloidiasis following treatment with high-dose corticosteroids and tocilizumab. Screening for Strongyloides infection should be pursued in individuals with COVID-19 who originate from endemic regions before initiating immunosuppressive therapy.
All Keywords
【초록키워드】 Corticosteroid, Treatment, therapy, Tocilizumab, Infection, SARS-CoV-2 virus, Screening, global pandemic, Region, fungal, Bacterial, Endemic, immunosuppressive, COVID-19 patient, High-dose, strongyloidiasis, individuals with COVID-19, with COVID-19, 【제목키워드】 with COVID-19,
【초록키워드】 Corticosteroid, Treatment, therapy, Tocilizumab, Infection, SARS-CoV-2 virus, Screening, global pandemic, Region, fungal, Bacterial, Endemic, immunosuppressive, COVID-19 patient, High-dose, strongyloidiasis, individuals with COVID-19, with COVID-19, 【제목키워드】 with COVID-19,